EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis

Peter Youssef, Sabina Ciciriello, Talib Tahir, Joanna Leadbetter, Belinda Butcher, Miriam Calao, Nicole Walsh, Catherine O'Sullivan, Tegan Smith, Geoffrey Littlejohn

Rheumatology and Therapy · 2025-02 · 12 (1) · 173-202

DOI: 10.1007/s40744-024-00736-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 06.01.2025. Verfasst von Peter Youssef und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Musculoskeletal Health at University of Sydney, Sydney, NSW, Australia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie Pty Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

AustraliaBiologic disease-modifying antirheumatic drug (bDMARD)Janus kinase inhibitor (JAKi)PersistenceReal-world effectivenessRemissionRheumatoid arthritis (RA)Targeted synthetic disease-modifying antirheumatic drug (tsDMARD)Tumor necrosis factor inhibitor (TNFi)Upadacitinib (UPA)

Autor:innen und Institutionen

  • Institute for Musculoskeletal Health at University of Sydney, Sydney, NSW, Australia.
  • Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
  • OPAL Rheumatology Ltd, Sydney, NSW, Australia.
  • The Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Coburg Rheumatology Service, Coburg, VIC, Australia.
  • WriteSource Medical Pty Ltd, Lane Cove, NSW, Australia.

Förderung

  • AbbVie Pty Ltd

Zitieren

APA

Youssef, P., Ciciriello, S., Tahir, T., Leadbetter, J., Butcher, B., Calao, M., Walsh, N., O'Sullivan, C., Smith, T., & Littlejohn, G. (2025). Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis. Rheumatology and Therapy, 12(1), 173-202. https://doi.org/10.1007/s40744-024-00736-4

Vancouver

Youssef P, Ciciriello S, Tahir T, Leadbetter J, Butcher B, Calao M, et al. Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis. Rheumatology and Therapy. 2025;12(1):173-202. doi:10.1007/s40744-024-00736-4

BibTeX
@article{Youssef2025,
  author = {Youssef, Peter and Ciciriello, Sabina and Tahir, Talib and Leadbetter, Joanna and Butcher, Belinda and Calao, Miriam and Walsh, Nicole and O'Sullivan, Catherine and Smith, Tegan and Littlejohn, Geoffrey},
  title = {Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis},
  journal = {Rheumatology and Therapy},
  year = {2025},
  volume = {12},
  number = {1},
  pages = {173--202},
  doi = {10.1007/s40744-024-00736-4}
}
Kostenlos starten →